More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$8.08B
EPS
-2.9
P/E ratio
--
Price to sales
26.05
Dividend yield
--
Beta
2.174567
Previous close
$107.48
Today's open
$106.81
Day's range
$104.20 - $118.50
52 week range
$74.50 - $122.20
show more
CEO
David P. Meeker
Employees
414
Headquarters
Boston, MA
Exchange
NASDAQ Global Market
Shares outstanding
69330906
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Rhythm Pharmaceuticals Says Rare Obesity Drug Delivers Sustained Two-Year BMI Reductions
Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) on Monday presented two-year Phase 3 setmelanotide results and global diagnostic criteria at ObesityWeek 2026, highlighting sustained weight reductions and earlier diagnosis for acquired hypothalamic obesity (HO).
Benzinga • Nov 17, 2026

Rhythm drug shows sustained weight reduction in patients with brain damage-related obesity
Rhythm drug shows sustained weight reduction in patients with brain damage-related obesity
Reuters • Nov 16, 2026

Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026
– Two-year results from Phase 3 TRANSCEND trial showed continuous setmelanotide therapy sustained BMI reductions in patients with acquired hypothalamic obesity –
GlobeNewsWire • Nov 16, 2026

Rhythm Pharmaceuticals: Bull Case Intact, But The Market Is Pricing In A Lot
Rhythm Pharmaceuticals maintains strong commercial momentum, with IMCIVREE sales up 79.5% YoY and a broadening prescriber base in the acquired HO. RYTM's valuation is elevated at 27.4x trailing sales, reflecting high expectations for sustained growth and successful international launches. Takeover speculation, including a reported $124/share AstraZeneca bid, is supporting the share price but inflates the takeover premium over fundamentals.
Seeking Alpha • Nov 10, 2026

AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals
AstraZeneca recently made a roughly $10 billion offer to buy Rhythm Pharmaceuticals, according to people familiar with the matter, a deal that would expand its portfolio of rare disease treatments.
WSJ • Nov 4, 2026

Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome
-- Expanded guidance based on additional evidence demonstrating the benefits of IMCIVREE in adults living with Bardet-Biedl syndrome -- BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the National Institute for Health and Care Excellence (NICE) has issued a positive guidance for IMCIVREE® (setmelanotide) to include adults living with genetically confirmed Bardet-Biedl syndrome (BBS).
GlobeNewsWire • Nov 4, 2026

Rhythm Pharmaceuticals Q3 Earnings Call Highlights
Rhythm Pharmaceuticals NASDAQ: RYTM reported third-quarter global net product sales of $92.1 million, up 29% sequentially, as the company cited a strong early U.S. launch for IMCIVREE in acquired hypothalamic obesity, or acquired HO. The company also outlined plans to advance bivamelagon into Phase III studies for acquired HO and Prader-Willi syndrome, while expanding its international commercial footprint.
MarketBeat • Nov 3, 2026

Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2026 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 3, 2026

Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update
-- Strong U.S. launch momentum for IMCIVREE ® (setmelanotide) for acquired hypothalamic obesity (HO) continues with more than 700 patient start forms as of September 30, 2026 -- -- Third quarter 2026 net product revenue from global sales of IMCIVREE of $92.1 million, an increase of 29% from the prior quarter -- -- Commercial launch of IMCIVREE in Japan for patients with acquired HO underway -- -- Bivamelagon to advance into pivotal development in Prader-Willi syndrome --
GlobeNewsWire • Nov 3, 2026

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Beats Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to a loss of $0.82 per share a year ago.
Zacks Investment Research • Nov 3, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Rhythm Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.